Prabhudas Lilladher Recommends Buying Eris Lifesciences, Sets Rs 1,500 Target

Prabhudas Lilladher says Eris Lifesciences’ Q2FY27 EBITDA was INR 3.1bn, up 7% year over year and in line with its estimate. The broker expects improvement from H2FY27E/FY28E.